2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Leukemia, Myeloid, Acute
28
Lymphoma
26
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24
Breast Neoplasms
22
Multiple Myeloma
21
Lymphoma, Large B-Cell, Diffuse
21
Carcinoma, Non-Small-Cell Lung
21
Lymphoma, Non-Hodgkin
19
Lymphoma, Mantle-Cell
17
Lymphoma, Follicular
16
Hodgkin Disease
15
Lymphoma, T-Cell, Cutaneous
13
Glioblastoma
13
Leukemia, Lymphocytic, Chronic, B-Cell
12
Brain Neoplasms
12
Recurrence
11
Neuroblastoma
11
Myelodysplastic Syndromes
11
Mycosis Fungoides
11
Lymphoma, B-Cell, Marginal Zone
11
Leukemia
11
Burkitt Lymphoma
11
Neoplasms
10
Sezary Syndrome
9
Congenital Abnormalities
9
Prostatic Neoplasms
8
Lymphoma, Large-Cell, Anaplastic
8
Squamous Cell Carcinoma of Head and Neck
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
7
Neoplasms, Plasma Cell
7
Interventions
Cisplatin
57
Pemetrexed
46
pembrolizumab
18
Nivolumab
15
Carboplatin
15
Gemcitabine
14
Cyclophosphamide
13
Radiotherapy
10
Drug Therapy
9
atezolizumab
8
Platinum
7
Ipilimumab
7
Doxorubicin
7
durvalumab
6
1,2-diaminocyclohexaneplatinum II citrate
6
tremelimumab
5
sodium thiosulfate
5
Vinorelbine
5
Radiotherapy, Intensity-Modulated
5
Interleukin-2
5
Chemotherapy, Adjuvant
5
Cerebral Decortication
5
sargramostim
4
fludarabine
4
defactinib
4
aldesleukin
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
cediranib
3
Photochemotherapy
3
Neoadjuvant Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
Vorinostat
×
Clear all
NCT01353482
2012-03-22
MESO-02
University College, London
Phase 1/2
Withdrawn